EMA Delays Decision on Clinical Trial Data until October - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
EMA Delays Decision on Clinical Trial Data until October

Source: Applied Clinical Trials

The European Medicines Agency (EMA) has postponed formal adoption of the policy on publication of clinical trial data until its October 2, 2014 meeting.

Further clarifications on the wording and practical arrangements will be discussed by members of the management board, who have confirmed their general support for the overall aims and objectives of the policy, including the more user-friendly amendments proposed by EMA Executive Director Guido Rasi that would allow data to be downloaded, saved or printed for academic and non-commercial research purposes.

The EMA says it welcomes “this additional round of joint reflections and respects all opinions, as well as the views expressed by several Member States, which largely reproduce the complexity of the debate on both political and technical aspects which have emerged during the previous general and more targeted consultation phases.” In the last 12 months, it has attempted to strike a balance between proactive data disclosure, the absolute need to protect personal data and the concerns relating to the protection of commercially confidential information.

The agency remains committed to introducing this additional measure towards transparency as soon as possible, so as to enhance public awareness and confidence in the EU authorization system for medicinal products. It also emphasizes that the new policy, if approved, will be without prejudice to the provisions of Regulation (EC) No 1049/2001 on access to documents and the new clinical trial Regulation (EC) No 536/2014, which will become applicable in 2016 at the earliest and will apply to clinical trials conducted in the EU.

Read the full release here.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here